Somed & OTESALY OEM: Premium Face Contouring Injectables from China’s GMP-Certified Manufacturer

What does it take to launch a face contouring injectable line that earns consistent repeat orders from clinic partners and passes strict regulatory checks across EU, US, and MENA markets? Ask the teams behind Somed and OTESALY—two globally recognized medical aesthetics brands that have built their popular dermal filler lines through OEM partnership with a China-based manufacturer. For years, brands and clinic groups around the world have sourced premium injectables from Chinese production facilities, drawn by consistent quality, flexible customization, and cost efficiency that cuts out layers of middleman markup. Many first-time entrants to the space run into predictable roadblocks, though: hidden supply chain risks, inflexible order terms, missing compliance paperwork, and formula inconsistencies that lead to poor patient outcomes.

Real-World Lessons From Brands That Built Successful Contouring Injectable Lines

Take Klara, founder of a Poland-based startup aesthetics brand that launched in 2021. She initially sourced face contouring fillers from a small-scale supplier offering prices 30% below the industry average, drawn by the promise of fast delivery and low upfront cost. The first 2,000-unit shipment was seized at EU customs when the supplier could not produce valid CE certification documentation. Third-party testing of retained samples found BDDE crosslinker residue 4 times the EU safety limit, with unlisted impurities in the HA gel. Klara lost €120,000 in inventory and missed the peak Q4 aesthetics season, setting her brand launch back 8 full months.

She connected with AIMA International Group Co., Ltd. at the Dubai Derma exhibition in 2022, initially skeptical of Chinese manufacturers after her prior loss. The team provided full SGS test reports, CE certification, and ISO 13485 documentation before she even requested samples, and offered a 100-unit trial order with no long-term commitment. She tested the samples across 3 partner clinics in Warsaw, where doctors noted the gel had consistent push force, high cohesivity that prevented migration in the jawline, and zero reports of prolonged redness or irritation in patients. Within 18 months, her brand was selling over 12,000 units of contouring filler annually across 120 clinics in Poland, Czechia, and Slovakia.

A second example comes from DermaOne, a large medical aesthetics chain based in Saudi Arabia with 17 clinic locations. For years, the group retailed international branded contouring fillers, with profit margins capped at 18% after distributor fees and regional markup. The team sought to launch a private-label line tailored to MENA patient needs, with three distinct filler formulations: a high-cohesivity gel for sharp jawline and chin definition, a medium-elasticity gel for apple cheek and temple volume restoration, and a soft, low-density gel for under-eye and perioral contour blending. Three separate suppliers turned down their request, either requiring a 50,000-unit minimum order per SKU or refusing to adjust formula crosslinking levels to match their specifications. AIMA’s R&D team pulled 3 pre-vetted formulations from its library of over 1,000 mature recipes, adjusted lidocaine content to match MENA patient pain tolerance preferences, and fulfilled the initial order of 500 units per SKU with an 18-day lead time. The private label line now drives 62% profit margins for DermaOne, with quarterly repurchase rates holding steady at 78% across all locations.

Core Technology That Defines Premium Face Contouring Injectable Quality

Face contouring injectables differ dramatically from superficial wrinkle fillers in performance requirements. Gels used for jawline, chin, and cheek contouring need enough cohesivity to hold shape without migrating, enough elasticity to move naturally with facial expressions, and low enough impurity levels to avoid adverse reactions long after injection. AIMA holds two core production technologies that set its injectables apart from generic market offerings, used across all Somed and OTESALY OEM production runs.

NASHA (Non-Animal Stabilized Hyaluronic Acid) technology forms the base of all HA filler formulations. Unlike older production methods that source HA from rooster combs (carrying risk of animal protein allergy), NASHA uses biofermented HA, stabilized through a proprietary crosslinking process to create a uniform 3D gel matrix. The process allows precise adjustment of gel cohesivity from 12Pa·s for superficial contouring to 28Pa·s for deep structural support, so gels stay placed at the injection layer without spreading to surrounding tissue. Patients avoid the overfilled, “puffy” look common with low-cohesivity gels that shift under the skin, with results that degrade evenly over the product lifespan rather than collapsing abruptly.

HICE (Highly Integrated Crosslinking Embedding) technology addresses one of the most common causes of filler-related adverse events: free BDDE crosslinker residue. Traditional crosslinking methods leave trace amounts of unbound BDDE in the gel, which can trigger chronic inflammation, granulomas, and prolonged swelling in sensitive patients. The HICE process fully embeds crosslinker molecules within the HA molecular matrix, reducing free BDDE residue to less than 0.001mg/kg—50 times lower than the 0.02mg/kg limit set by EU CE regulations. Post-market clinical data across 500,000+ injected units shows an adverse reaction rate of less than 0.02%.

All production runs use medical-grade, non-animal sourced HA priced at $45,000 per kilogram, sourced exclusively from suppliers with active CE GMP certification. Every incoming batch of raw material undergoes third-party SGS testing for purity, endotoxin levels, and molecular weight before entering the production floor. The brand’s core contouring injectable line, Facefill, is formulated explicitly for facial sculpting use cases, with SKUs tailored to every contour layer:

• Facefill Fine: Low-density gel for superficial contour blending around the eyes and mouth
• Facefill Derm: Medium-elasticity gel for mid-layer volume restoration in the cheeks and temples
• Facefill Deep: High-cohesivity gel for deep structural contouring of the jawline, chin, and nose bridge

All SKUs are available with 0.3% lidocaine to reduce patient discomfort during injection, with a smooth, consistent push force that reduces hand fatigue for clinicians during long procedures. Results last 12-18 months, with full natural metabolism by the body with no residual deposit.

OEM Capabilities Built For Every Brand Stage

Founded in 2003, AIMA operates a 4,800 square meter modern production facility purpose-built for medical aesthetics injectable manufacturing. The space houses Class 100 GMP cleanrooms and 3 dedicated production lines, built to meet Class III medical device production standards.

Total annual production capacity hits 5 million units, with monthly output of up to 50,000 units to accommodate both small test runs and large bulk orders. Sample orders ship in 3-5 working days, with standard bulk order lead times of 15-20 days, plus expedited production options for brands facing tight launch deadlines. Unlike many OEM providers that lock clients into rigid, one-size-fits-all packages, AIMA offers end-to-end customization for face contouring injectable lines:

• Market-specific brand positioning support, including regional trend data for contouring preferences across North America, EU, MENA, and APAC markets
• Custom logo design and packaging options, including sterile pre-filled syringes, sealed blister packs, and multi-language instruction manuals aligned with local regulatory labeling requirements
• Full formula adjustment capabilities, from HA concentration and crosslink density to lidocaine content and gel texture, matched to your brand’s target use cases and price point
• Flexible order terms with no MOQ pressure for new brands testing product-market fit, plus tiered bulk discounts for established brands and large clinic chains scaling their product lines

To date, the team has delivered custom injectable solutions for over 521 brands across 60+ countries, including long-term OEM partnerships with Somed and OTESALY. The company holds an industry award as one of the Top 10 Dermal Filler Manufacturers globally, with a presence at 12+ international medical aesthetics trade shows each year to connect directly with brand partners and clinic owners.

Compliance And Support That Removes Supply Chain Risk

The medical aesthetics injectable space is full of suppliers offering rock-bottom prices, but many cut corners that put brands at serious risk. Common issues include fake CE certificates, industrial-grade HA raw material not approved for human injection, unsterile production environments that lead to product contamination, and zero after-sales support when issues arise. Brands that choose these suppliers often face seized shipments, regulatory fines, and permanent damage to their reputation among clinic partners and patients.

AIMA’s production and quality control systems are built to eliminate these risks for all OEM partners, with transparent, verifiable processes at every step:

• Full alignment with ISO 13485 quality management system standards, with regular third-party audits of production facilities and quality control processes
• Active EU CE certification for dermal filler products, plus US FDA VCRP (Voluntary Cosmetic Registration Program) registration, with full documentation packages provided to support customs clearance and market registration in target regions
• Batch-specific Certificate of Analysis (CoA) for every shipment, including in-house lab test results and third-party SGS reports for HA purity, crosslinker residue, sterility, and endotoxin levels
• Dedicated account support for every OEM partner, including technical training materials for clinic teams, adverse event troubleshooting guidance, and regulatory consultation for new market entry

Many new partners come to AIMA expecting to pay a premium for this level of quality and support, and are surprised to find production costs 35-40% lower than comparable European or North American OEM providers, with no hidden fees or mandatory add-on services. Why pay 2-3 times the price for identical raw material quality and production standards, when you can work directly with the manufacturer that builds products for many of the brands already selling in your market?

Brands and clinic groups exploring OEM options for premium face contouring injectables can request free samples, custom quotes, or a virtual walkthrough of the production facility directly through supplierfiller.com. The AIMA team responds to all inquiries within 24 hours, with tailored recommendations based on your target market, brand stage, and product goals.